Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. lifted its holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) by 11.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,100 shares of the company’s stock after purchasing an additional 5,673 shares during the quarter. American Century Companies Inc. owned about 0.09% of Inozyme Pharma worth $255,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in INZY. Values First Advisors Inc. acquired a new stake in shares of Inozyme Pharma in the 2nd quarter worth $76,000. Rhumbline Advisers boosted its position in shares of Inozyme Pharma by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after purchasing an additional 13,867 shares in the last quarter. Superstring Capital Management LP acquired a new stake in shares of Inozyme Pharma in the 4th quarter worth $528,000. Bank of New York Mellon Corp boosted its position in shares of Inozyme Pharma by 16.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock worth $851,000 after purchasing an additional 26,464 shares in the last quarter. Finally, Kennedy Capital Management LLC boosted its position in shares of Inozyme Pharma by 52.2% in the 1st quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock worth $3,352,000 after purchasing an additional 150,120 shares in the last quarter. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Stock Performance

Shares of INZY stock opened at $5.17 on Friday. The stock has a market cap of $319.80 million, a PE ratio of -3.77 and a beta of 1.51. The business has a 50-day simple moving average of $5.20 and a 200-day simple moving average of $5.11. The company has a quick ratio of 9.84, a current ratio of 9.84 and a debt-to-equity ratio of 0.48. Inozyme Pharma, Inc. has a 52-week low of $2.69 and a 52-week high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). On average, equities analysts expect that Inozyme Pharma, Inc. will post -1.68 EPS for the current year.

Wall Street Analyst Weigh In

INZY has been the subject of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price target (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Stifel Nicolaus initiated coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Inozyme Pharma in a research report on Thursday, August 8th. Wedbush reaffirmed an “outperform” rating and set a $15.00 price target on shares of Inozyme Pharma in a research report on Monday, September 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Inozyme Pharma in a research report on Tuesday, August 6th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $16.14.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.